PATENT CLAIM ANALYSIS

Application Number: 16170134
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["514", "234200"]

Abstract:
The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.

Claim (Index 6):
The method of  claim 5 , wherein the metformin is present in the composition in a dosage strength of 500 mg, 850 mg or 1000 mg in form of immediate release metformin; or 500 mg, 750 mg, 1000 mg, 1500 mg or 2000 mg in form of extended release metformin.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 97.0
- Lexical Diversity: 1.05556
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15616974', '15918401', '15354053', '14918727', '14928048']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7224191885949627
- 35 USC 102 Novelty (BERT): 0.6001534716010191
- Combined Prediction Score: 0.7101926168955683
- Mean Citation Score: 371.19762
- Max Citation Score: 489.67908
- Similarity Product: 485.9865847677827

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test